Hello All
This is to let you know NICE have announced today that olaparib will be available as second line maintenance treatment via the Cancer Drugs Fund, for those with the BRCA mutation.
You can read more on the NICE website here: nice.org.uk/guidance/TA620
You would also need to be platinum sensitive.
Essentially this means there is a greater choice of PARP inhibitors available second-line for those with the BRCA mutation, alongside niraparib and rucaparib, which are both available second-line via the Cancer Drugs Fund regardless of BRCA status.
If you have any questions about this, please do get in touch with us.
Best wishes
Anna
Ovacome Support